Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 152

Results For "NIT"

5871 News Found

Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India
News | September 16, 2025

Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India

Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB


Cadila launches nutritional replenisher ‘Nu Nutridac’ capsule
News | September 16, 2025

Cadila launches nutritional replenisher ‘Nu Nutridac’ capsule

Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders


Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China
Drug Approval | September 15, 2025

Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China

This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis


Biocon Foundation constructs new high school building in Karnataka
News | September 13, 2025

Biocon Foundation constructs new high school building in Karnataka

Biocon Foundation is also expanding its reach with this first initiative in Channapatna region


VedaBio to use Mammoth Biosciences’ CRISPR-based technology for diagnostic applications
News | September 12, 2025

VedaBio to use Mammoth Biosciences’ CRISPR-based technology for diagnostic applications

CRISPR-based detection enables highly specific molecular recognition


Shukra Pharmaceuticals inks distribution tie-up with Wockhardt
Supply Chain | September 12, 2025

Shukra Pharmaceuticals inks distribution tie-up with Wockhardt

The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)


Kytopen collaborates with BlueWhale Bio for cell therapy manufacturing
Biotech | September 12, 2025

Kytopen collaborates with BlueWhale Bio for cell therapy manufacturing

Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients